RIPK2

Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics, Cadrenal and Inovio: Altimmune to test its incretin in addiction : Following the path set by Novo Nordisk last week , Altimmune said Thursday at its R&D Day that it plans to begin trials of its injectable GLP-1/glucagon agonist pemvidutide in alcohol use disorder as well as alcoholic liver disease. Stifel analysts wrote in a note on Thursday that Altimmune has animal data that suggest pemvidutide could reduce daily alcohol intake by around half. They also cautioned that additional data would be needed to validate the hypothesis. — Elizabeth Cairns Tarsus Pharmaceuticals’ expected $125 million stock sale: The drugmaker said the funds from the public offering will be used to support the US commercialization of Xdemvy, eye drops for irritation caused by tiny mites. Tarsus also said the funds will be used to advance its experimental ocular rosacea and lyme disease drugs. — Lei Lei Wu Heidelberg amends royalty deal: The company signed an agreement with HealthCare Royalty a year ago to provide royalties to Zircaix, or TLX250-CDx, an imaging agent for some kidney cancers. While the total value of the milestones remains the same at $90 million, the companies changed the deal so that Heidelberg will receive $20 million immediately rather than get $15 million as a sales milestone. They also reduced the FDA approval milestone to $70 million from $75 million. (That milestone will be further reduced if approval comes after 2025.) Heidelberg licensed the drug to Telix in 2017, and a rolling FDA submission was initiated in 2023. — Max Gelman Accropeutics raises $12M to fund IBD asset : The Series B-plus round was led by Shenzhen Capital Group and is set to extend the biotech’s cash runway into the second half of next year. The proceeds will be used for the ongoing Phase 1b trial of Accropeutics’ RIPK2 inhibitor, known as AC-101, in ulcerative colitis. Accropeutics also has a mid-stage TYK2/JAK1 inhibitor in development for psoriasis and a RIPK1 inhibitor for graft-versus-host disease. — Elizabeth Cairns Allarity Therapeutics settles with SEC: The company will pay $2.5 million to the Securities and Exchange Commission after the regulator alleged Allarity executives concealed from investors that the FDA had recommended against approving dovitinib, an experimental cancer therapy. The company did not admit or deny the allegations. — Jaimy Lee Cadrenal is still seeking a partner for tecarfarin: It wants help advancing the oral vitamin K antagonist into a pivotal trial for patients with left ventricular assist devices and other rare cardiovascular conditions. — Jaimy Lee Inovio’s DNA therapy is durable in early trial : The company said Thursday that a Phase 1 trial proves the concept of its so-called DMAbs. The DNA plasmids encoding antibodies derived from Evusheld, AstraZeneca’s Covid-19 prophylactic, were given to patients and were translated into the proteins by the patient’s own cells. All subjects who reached week 72 had biologically relevant levels of the antibodies, according to Inovio, and the expressed DMAbs bound to the SARS-CoV-2 spike protein confirmed functional activity. However, the company did not say whether the approach prevented infections . — Elizabeth Cairns

Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). Cash runway extended into the second half of 2026 NEW YORK and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the closing of its $12 million Series B Plus financing. The round was led by Shenzhen Capital Group (SCGC), an existing investor, with participation from Morningside Ventures, also an existing investor, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). The proceeds from the Series B Plus financing will be used to generate more clinical data for AC-101, a RIPK2 inhibitor, in an ongoing Phase Ib clinical trial for patients with Ulcerative Colitis (UC). Accropeutics' other clinical-stage assets include AC-201, a selective TYK2/JAK1 inhibitor, currently in an ongoing Phase II trial for patients with moderate-to-severe Psoriasis, and for multiple additional indications; and AC-003, a RIPK1 inhibitor, currently in an ongoing Phase Ib trial for patients with acute Graft-versus-Host Disease (aGvHD). The company also has multiple I&I assets in the pre-clinical stage. Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accropeutics, stated: " With this round of financing, we are able to continue advancing our lead programs and solidify our position as an innovative, multi-program, clinical-stage biotech company. I am grateful to our existing and new investors, who share our vision that we can transform the treatment landscape for a wide range of I&I diseases with potentially best-in-class therapies. " About Accropeutics Accropeutics Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for immune mediated inflammatory disease, by targeting molecular mechanisms of regulated cell death. The company has a robust portfolio of innovative compounds in various stages of development, ranging from lead optimization to clinical testing. AC-101, a selective RIPK2 inhibitor, has completed Phase I clinical trials in Australia and China, and is currently undergoing a Phase Ib trial for Ulcerative Colitis (UC). AC-201, a selective TYK2/JAK1 inhibitor, has completed Phase I study in Australia and China, and is currently undergoing a Phase II trial for Psoriasis in China. AC-003, a selective RIPK1 inhibitor, has completed Phase I clinical trials in China and the United States as of August 2023, and is currently undergoing a Phase Ib clinical trial in aGVHD. Accropeutics' pipeline also includes several assets in the research and pre-clinical stages of development. Accropeutics owns global rights for all of its assets, and boasts 23 issued patents in China, Japan, Korea, US and the EU. For more information, visit Contacts Kenneth Gao SVP, Corporate Development & Strategy [email protected] SOURCE Accropeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEW YORK, NY, USA I February 13, 2025 I Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the dosing of their first patient in the Phase Ib clinical trial of AC-101. AC-101 is a novel RIPK2 inhibitor being developed for the treatment of moderate-to-severe Ulcerative Colitis (UC). This multi-center, open-label clinical trial will evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of AC-101 in Chinese patients with moderate-to-severe UC. Accropeutics recently secured U.S. FDA IND clearance for AC-101 to enable its planned Phase 2 Multi-Regional Clinical Trial (MRCT) for this indication. Dr. Xiaohu Zhang, co-founder and CEO of Accropeutics said, “Dosing of the first patient in AC-101’s Phase 1b study represents a significant step towards advancing this novel oral therapeutic for treatment of patients suffering from Ulcerative Colitis. We believe that RIPK2 comprises a critical target in the pathogenesis of inflammatory bowel disease, including Ulcerative Colitis and Crohn’s Disease, and that targeting it with AC-101 will provide a novel front-line option to patients in urgent need of efficacious, non-immunosuppressive treatments.” About Ulcerative Colitis (UC) Ulcerative Colitis (UC), is a chronic, immune-mediated, inflammatory disease of the digestive tract, characterized by the inflammation of the large intestine and an intermittent relapsing–remitting disease course. Recurring UC flares lead to significant cumulative morbidity and long-standing disease is associated with significant risk of developing colorectal cancer. Patients with active disease are more likely to experience psychological comorbidity, including stress, anxiety and depression, that significantly impair their quality of life and work productivity. While many advanced therapeutics exist to manage moderate-to-severe UC, the majority of these drugs associate with less than impressive clinical remission rates (20–30%), along with a high incidence of secondary loss of response in patients who initially responded. About RIPK2 Receptor interacting protein kinase 2 (RIP2 or RIPK2) is a member of the receptor interacting serine/threonine protein kinase family. NOD/RIPK2 dependent signaling pathway dysregulation is implicated in several forms of immune mediated inflammatory disease, including inflammatory bowel disease (IBD) and sarcoidosis. About AC-101 AC-101 was developed from the company’s “regulatory cell death and inflammation” drug discovery platform. Preclinical studies show that AC-101 effectively inhibits the release of the NOD-RIPK2 dependent inflammatory factors and significantly protects tissue damage in nonclinical in-vivo models. AC-101 has completed Phase I clinical testing in Australia and China with evidence of strong safety and PK/PD signal. About Accropeutics Accropeutics Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for immune mediated inflammatory disease, by targeting molecular mechanisms of regulated cell death. The company has a robust portfolio of innovative compounds in various stages of development, ranging from lead optimization to clinical testing. AC-003, a selective RIPK1 inhibitor, completed phase I clinical testing in China and the United States, and is undergoing phase Ib clinical trials in aGVHD. AC-201, a selective TYK2/JAK1 inhibitor, has completed Phase I testing in Australia and China, and is currently undergoing a Phase II psoriasis trial in China. The Accropeutics portfolio additionally includes several assets in research and preclinical stages of development. Accropeutics entirely owns global rights for all of its assets, and boasts 23 issued patents in China, Japan, Korea, US and the EU. SOURCE: Accropeutics